{"protocolSection": {"identificationModule": {"nctId": "NCT01131182", "orgStudyIdInfo": {"id": "0431-263"}, "secondaryIdInfos": [{"id": "2010_538"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)", "officialTitle": "An Open-Label, Randomized Naturalistic Study to Evaluate the Incidence of Hypoglycemia Comparing Sitagliptin With Sulfonylurea Treatment in Patients With Type 2 Diabetes During Ramadan Fasting"}, "statusModule": {"statusVerifiedDate": "2022-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-06-13", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2010-11-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-11-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-05-25", "studyFirstSubmitQcDate": "2010-05-25", "studyFirstPostDateStruct": {"date": "2010-05-26", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-12-15", "resultsFirstSubmitQcDate": "2011-12-15", "resultsFirstPostDateStruct": {"date": "2012-01-20", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2011-11-02", "dispFirstSubmitQcDate": "2011-11-02", "dispFirstPostDateStruct": {"date": "2011-11-06", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2022-08-24", "lastUpdatePostDateStruct": {"date": "2022-09-21", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will examine whether the incidence of hypoglycemia in patients fasting for Ramadan is lower when treated with sitagliptin as compared to sulfonylurea treatment.", "detailedDescription": "This study and NCT01340768 (MK-0431-262) have the same design but are conducted under separate protocols, in different countries, according to local guidelines."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus (T2DM)"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 1147, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sitagliptin", "type": "EXPERIMENTAL", "description": "Sitagliptin 100 mg administered orally daily as monotherapy or in combination with metformin over the Ramadan period.", "interventionNames": ["Drug: Sitagliptin phosphate", "Drug: Metformin"]}, {"label": "Sulfonylurea", "type": "ACTIVE_COMPARATOR", "description": "Sulfonylurea administered orally daily as monotherapy or in combination with metformin over the Ramadan period.", "interventionNames": ["Drug: Comparator: Sulfonylurea", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Sitagliptin phosphate", "description": "Sitagliptin 100 mg tablet administered orally once daily over the Ramadan period.", "armGroupLabels": ["Sitagliptin"], "otherNames": ["Januvia"]}, {"type": "DRUG", "name": "Comparator: Sulfonylurea", "description": "Sulfonylurea (glibenclamide, glimepiride, or gliclazide) administered orally daily over the Ramadan period as per physician's prescription", "armGroupLabels": ["Sulfonylurea"]}, {"type": "DRUG", "name": "Metformin", "description": "Participants could continue pre-study metformin as concomitant therapy during the study.", "armGroupLabels": ["Sitagliptin", "Sulfonylurea"], "otherNames": ["Glucophage"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Proportion of Participants With at Least One Symptomatic Hypoglycemic Event", "description": "Symptomatic hypoglycemic event was determined based on the participant's self-reported symptoms including faintness, headache, confusion, anxiety, sweating, tremor, palpitation, nausea, pallor, dizziness, hunger, and sudden behavioral change.", "timeFrame": "30 days: first day of Ramadan (August 11) to last day of Ramadan (September 10)"}], "secondaryOutcomes": [{"measure": "Proportion of Participants With at Least One Symptomatic or Asymptomatic Hypoglycemic Event", "description": "Hypoglycemic event was based on the participant's self-report and/or finger-stick blood glucose level. Symptomatic hypoglycemic symptoms included faintness, headache, confusion, anxiety, sweating, tremor, palpitation, nausea, pallor, dizziness, hunger, and sudden behavioral change.", "timeFrame": "30 days: first day of Ramadan (August 11) to last day of Ramadan (September 10)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Muslim men and women with type 2 diabetes\n* Participants who intend to fast during the month of Ramadan\n* Participants who have been on a stable dose of sulfonylurea for at least three months\n\nExclusion Criteria:\n\n* Participants with type 1 diabetes mellitus\n* Pregnant or breast feeding women\n* Participants with hypersensitivity or contraindication to dipeptidyl peptidase (DPP-4) treatment\n* Participants on insulin\n* Participants on any class of oral diabetic therapy other than sulfonylurea or metformin", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "21951832", "type": "RESULT", "citation": "Al Sifri S, Basiounny A, Echtay A, Al Omari M, Harman-Boehm I, Kaddaha G, Al Tayeb K, Mahfouz AS, Al Elq A, Radican L, Ozesen C, Katzeff HL, Musser BJ, Suryawanshi S, Girman CJ, Davies MJ, Engel SS; 2010 Ramadan Study Group. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract. 2011 Nov;65(11):1132-40. doi: 10.1111/j.1742-1241.2011.02797.x. Epub 2011 Sep 27."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf", "url": "http://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Of the 1147 participants enrolled in the study, 1066 participants were randomized to treatment.", "groups": [{"id": "FG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg administered orally daily over the Ramadan period"}, {"id": "FG001", "title": "Sulfonylurea", "description": "Sulfonylurea administered orally daily over the Ramadan period as per physician's prescription"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "529"}, {"groupId": "FG001", "numSubjects": "537"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "513"}, {"groupId": "FG001", "numSubjects": "521"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "16"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "15"}]}, {"type": "Other Reason", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg administered orally daily over the Ramadan period. All participants as treated population, n=507."}, {"id": "BG001", "title": "Sulfonylurea", "description": "Sulfonylurea administered orally daily over the Ramadan period as per physician's prescription. All participants as treated population, n=514."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "507"}, {"groupId": "BG001", "value": "514"}, {"groupId": "BG002", "value": "1021"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55", "spread": "11"}, {"groupId": "BG001", "value": "55", "spread": "10"}, {"groupId": "BG002", "value": "55", "spread": "11"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "238"}, {"groupId": "BG001", "value": "259"}, {"groupId": "BG002", "value": "497"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "269"}, {"groupId": "BG001", "value": "255"}, {"groupId": "BG002", "value": "524"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Proportion of Participants With at Least One Symptomatic Hypoglycemic Event", "description": "Symptomatic hypoglycemic event was determined based on the participant's self-reported symptoms including faintness, headache, confusion, anxiety, sweating, tremor, palpitation, nausea, pallor, dizziness, hunger, and sudden behavioral change.", "populationDescription": "All participants as treated population consisted of all randomized participants who received at least one dose of study treatment and returned at least one completed diary card during the Ramadan period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "proportion of participants", "timeFrame": "30 days: first day of Ramadan (August 11) to last day of Ramadan (September 10)", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg administered orally daily over the Ramadan period."}, {"id": "OG001", "title": "Sulfonylurea", "description": "Sulfonylurea administered orally daily over the Ramadan period as per physician's prescription."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "507"}, {"groupId": "OG001", "value": "514"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.07"}, {"groupId": "OG001", "value": "0.13"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0005", "pValueComment": "Assessed for relative risk using prior therapy (monotherapy or combination therapy) as a stratification factor.", "statisticalMethod": "Cochran-Mantel-Haenszel", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Proportion of Participants With at Least One Symptomatic or Asymptomatic Hypoglycemic Event", "description": "Hypoglycemic event was based on the participant's self-report and/or finger-stick blood glucose level. Symptomatic hypoglycemic symptoms included faintness, headache, confusion, anxiety, sweating, tremor, palpitation, nausea, pallor, dizziness, hunger, and sudden behavioral change.", "populationDescription": "All participants as treated population consisted of all randomized participants who received at least one dose of study treatment and returned at least one completed diary card during the Ramadan period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Proportion of participants", "timeFrame": "30 days: first day of Ramadan (August 11) to last day of Ramadan (September 10)", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg administered orally daily over the Ramadan period."}, {"id": "OG001", "title": "Sulfonylurea", "description": "Sulfonylurea administered orally daily over the Ramadan period as per physician's prescription."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "507"}, {"groupId": "OG001", "value": "514"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.08"}, {"groupId": "OG001", "value": "0.18"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "All participants as treated population consisted of all randomized participants who received at least one dose of study treatment and returned at least one completed diary card during the Ramadan period.", "eventGroups": [{"id": "EG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg administered orally daily over the Ramadan period.", "seriousNumAffected": 0, "seriousNumAtRisk": 507, "otherNumAffected": 34, "otherNumAtRisk": 507}, {"id": "EG001", "title": "Sulfonylurea", "description": "Sulfonylurea administered orally daily over the Ramadan period as per physician's prescription.", "seriousNumAffected": 3, "seriousNumAtRisk": 514, "otherNumAffected": 68, "otherNumAtRisk": 514}], "seriousEvents": [{"term": "Pancreatitis acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 507}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 514}]}, {"term": "Urinary Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 507}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 514}]}, {"term": "Ischaemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 507}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 514}]}], "otherEvents": [{"term": "Hunger", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.0", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 507}, {"groupId": "EG001", "numAffected": 35, "numAtRisk": 514}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "stats": [{"groupId": "EG000", "numAffected": 20, "numAtRisk": 507}, {"groupId": "EG001", "numAffected": 38, "numAtRisk": 514}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "stats": [{"groupId": "EG000", "numAffected": 25, "numAtRisk": 507}, {"groupId": "EG001", "numAffected": 44, "numAtRisk": 514}]}, {"term": "Tremor", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 507}, {"groupId": "EG001", "numAffected": 34, "numAtRisk": 514}]}, {"term": "Hyperhidrosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 13.0", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 507}, {"groupId": "EG001", "numAffected": 32, "numAtRisk": 514}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharpe & Dohme Corp", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Japan"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M10053", "name": "Hypoglycemia", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Dextromethorphan", "relevance": "HIGH"}, {"id": "M9018", "name": "Gliclazide", "relevance": "LOW"}, {"id": "M252104", "name": "Glimepiride", "relevance": "LOW"}, {"id": "M9017", "name": "Glyburide", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}